CHMP issues positive opinion for 20-Valent Pneumococcal Conjugate Vaccine for the prevention of vaccine-type pneumococcal pneumonia in adults- Pfizer.
The CHMP’s positive opinion will now be reviewed for this indication by the European Commission (EC). The decision on whether to approve PCV20, whose European Union (EU) trade name will be Apexxnar, will be made by the EC and will be applicable to all 27 EU member states plus Iceland, Lichtenstein and Norway.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies